Cyclic peptides for cancer therapy and prognosis assessment

October 3, 2018, National University of Singapore
Cyclic peptides for cancer therapy and prognosis assessment
Graphic depiction of the mechanism of action of the BC71 peptide by targeting cell-surface GRP78 in cancer. Credit: National University of Singapore

NUS biologists have developed cyclic peptides that can trigger cancer cell death without affecting healthy cells.

The glucose-regulated protein 78 kDa (known as GRP78) is emerging as a target for cancer therapy and a biomarker for cancer prognosis. It is usually produced in greater quantities in cells that are under stress conditions. In many types of cancers, GRP78 protein has been observed to be produced in abnormally large quantities and it tends to be found on the of cancer cells and cancer blood vessel endothelial cells.

A research team led by Prof GE Ruowen, Department of Biological Sciences, NUS has developed a cyclic peptide named BC71 which is able to effectively suppress tumour growth in murine models when delivered intravenously. BC71 peptide selectively accumulates in cancer, attaching itself onto the GRP78 protein present on the surface of cancer cells as well as cancer blood vessel endothelial cells, triggering cell death in the process. In , GRP78 protein is only present inside the cells and cannot be reached by BC71 peptide. However, in cancer cells and cancer blood vessel endothelial , there is a large amount of the GRP78 protein located on the cell surface.

Higher GRP78 protein levels in cancer typically correlate with poor prognosis and higher likelihood of drug resistance, with features of aggressive growth and high metastatic rate. As BC71 selectively targets cell-surface GRP78 proteins, this peptide can potentially be useful for these types of difficult to treat cancers.

Prof Ge said, "BC71 is small cyclic peptide with molecular weight of about 600 daltons. With further chemical modifications, it could be developed into more effective drug compounds with enhanced binding affinity to GRP78 protein and augmented death-inducing potency in ."

"In addition, radioisotope labelled BC71 have the potential to be used as a probe in (PET) imaging to determine how aggressive a cancer is in prognosis assessment," added Prof Ge.

Explore further: Getting a GRiP on chemoresistance: A review of GRP78 as a therapeutic target in cancer

More information: Chieh Kao et al. Proapoptotic Cyclic Peptide BC71 Targets Cell-Surface GRP78 and Functions as an Anticancer Therapeutic in Mice, EBioMedicine (2018). DOI: 10.1016/j.ebiom.2018.06.004

Related Stories

Getting a GRiP on chemoresistance: A review of GRP78 as a therapeutic target in cancer

March 1, 2018
Innate or acquired resistance to current standard-of-care therapies is a major hindrance to successful chemotherapeutic intervention. There is a critical need to elucidate the underlying mechanisms responsible for chemoresistance ...

Chinese herbal extract may help kill off pancreatic cancer cells

July 1, 2014
A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a ...

The secret to combating pancreatic cancer may lie in suppression of a common protein

May 22, 2017
New research from the Keck School of Medicine of the University of Southern California (USC) shows new promise in the fight against one of the most lethal forms of cancer. Studies in mice with a mutation present in 90 percent ...

Scientists identify protein involved in restoring effectiveness of common treatment for breast cancer

October 3, 2016
Breast cancer is the most frequently diagnosed cancer among women, with estrogen-receptor-positive (ER+) being the most common type. Drugs used to treat this cancer, such as tamoxifen and Faslodex, block the hormone estrogen ...

Ability to isolate and grow breast tissue stem cells could speed cancer research

May 7, 2014
(Medical Xpress)—By carefully controlling the levels of two proteins, researchers at the Salk Institute have discovered how to keep mammary stem cells—those that can form breast tissue—alive and functioning in the lab. ...

Single protein promotes resistance to widely used anti-estrogen drugs

July 2, 2012
Researchers at Georgetown Lombardi Comprehensive Cancer Center have uncovered a single molecule they say is a major determinant of resistance to anti-estrogen therapy used to treat or prevent breast cancer in high-risk women.

Recommended for you

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.